tert-butyl isopropyl disulfide | 43022-60-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 有机二硫化物
• 英文名称: tert-butyl isopropyl disulfide
• 英文别名: 2-Propyl-tert-butyldisulfid；Isopropyl-t-butyl-disulfid；tert-Butyl-isopropyl-disulfid；tert-butyl-isopropyl-disulfane；Disulfide, (1-methylethyl) (1,1-dimethylethyl)；2-methyl-2-(propan-2-yldisulfanyl)propane
• CAS: 43022-60-2
• 化学式: C₇H₁₆S₂
• 分子量: 164.336
• InChiKey: ZWAYVJUPUDGBIH-UHFFFAOYSA-N

物化性质

• 沸点：
  194.1±9.0 °C(Predicted)
• 密度：
  0.952±0.06 g/cm3(Predicted)
• 保留指数：
  1060;1060

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  50.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  叔丁基二硫 、 异丙基二硫醚 在 碘 作用下， 生成 tert-butyl isopropyl disulfide
  参考文献：
  名称：

  Cogwheel effect in dialkyl disulfides

  摘要：

  DOI：

  10.1021/ja00765a053

文献信息

• [EN] PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF<br/>[FR] PROMÉDICAMENTS DE PYRROLOBENZODIAZÉPINE ET CONJUGUÉS D'ANTICORPS DE CEUX-CI
  申请人：GENENTECH INC

  公开号：WO2018031662A1

  公开（公告）日：2018-02-15

  The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.

  这项发明涉及具有谷胱甘肽活化二硫键前药基团、DT-二氢呋喃酮酶活化醌前药基团或活化氧化物种的芳基硼酸或芳基硼酯前药基团的吡咯苯并二氮杂环烷单体和二聚体前药。该发明还涉及吡咯苯并二氮杂环烷前药二聚体-抗体共轭物。
• [EN] COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES OLIGONUCLÉOTIDES MODIFIÉS DE MANIÈRE RÉVERSIBLE ET LEURS UTILISATIONS
  申请人：DICERNA PHARMACEUTICALS INC

  公开号：WO2018039364A1

  公开（公告）日：2018-03-01

  Disclosed herein are glutathione-sensitive oligonucleotides and methods of using the same. Any oligonucleotide of interest may be modified with a glutathione-sensitive moiety, including oligonucleotides used for in vivo delivery, such as nucleic acid inhibitor molecules. Typically, the glutathione-sensitive moiety is used to reversibly modify the 2'-carbon of a sugar moiety in one or more nucleotides in the oligonucleotide, although other carbon positions may also be modified with the glutathione-sensitive moiety. Also disclosed are glutathione- sensitive nucleotide and nucleoside monomers, including glutathione-sensitive nucleoside phosphoramidites that can be used, for example, in standard oligonucleotide synthesis methods. In addition, glutathione-sensitive nucleotide and nucleoside monomers without a phosphoramidite can be used therapeutically, for example, as anti-viral agents.

  本文披露了谷胱甘肽敏感的寡核苷酸以及使用这些寡核苷酸的方法。感兴趣的任何寡核苷酸都可以通过谷胱甘肽敏感的基团进行修饰，包括用于体内传递的寡核苷酸，比如核酸抑制分子。通常，谷胱甘肽敏感的基团用于可逆地修饰寡核苷酸中一个或多个核苷酸的糖基的2'-碳，尽管其他碳位置也可以用谷胱甘肽敏感的基团进行修饰。此外，本文还披露了谷胱甘肽敏感的核苷酸和核苷单体，包括谷胱甘肽敏感的核苷酸磷酰胺二酰胺，例如，可以在标准寡核苷酸合成方法中使用。此外，没有磷酰胺二酰胺的谷胱甘肽敏感的核苷酸和核苷单体可以在治疗中使用，例如作为抗病毒剂。
• Protein-Polymer-Drug Conjugates
  申请人：Yurkovetskiy Aleksandr

  公开号：US20120321583A1

  公开（公告）日：2012-12-20

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种药物结合物。该结合物包括一种基于蛋白质的识别分子（PBRM）和一个聚合物载体，该载体被一个或多个-LD-D取代，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是分子量≦5 kDa的治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接剂。还公开了用于与PBRM结合形成聚合物-药物-PBRM结合物的聚合物支架，包括结合物的组成，其制备方法以及使用结合物或其组成物治疗各种疾病的方法。
• Auristatin Compounds and Conjugates Thereof
  申请人：Mersana Therapeutics, Inc.

  公开号：US20130309192A1

  公开（公告）日：2013-11-21

  Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently an Auristatin compound. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了Auristatin化合物及其共轭物。该共轭物包括基于蛋白质识别分子（PBRM）的识别分子和被取代一个或多个-LD-D的聚合物载体，其中蛋白质识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的Auristatin化合物。LD和LP是连接治疗剂和PBRM到聚合物载体的连接剂。本文还揭示了用于与PBRM共轭形成聚合物-药物-PBRM共轭物的聚合物支架，包括所述共轭物的组成，其制备方法以及使用共轭物或其组成治疗各种疾病的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150044160A1

  公开（公告）日：2015-02-12

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供一种药物偶联物。该偶联物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，其取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的，其分子量≦5 kDa，是一种治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接体。还公开了用于与PBRM偶联形成聚合物-药物-PBRM偶联物的聚合物支架，包括所述偶联物的组合物，其制备方法以及使用偶联物或其组合物治疗各种疾病的方法。

表征谱图